Based on the following article, this item was added to the Observatory page.

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Source The Lancet

Subscribe to the email digest

Doctors and Researchers can receive a weekly summary of relevant research articles.